Drug Approval | November 10, 2025
Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
